Compare BHR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | SPRO |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 135.5M |
| IPO Year | N/A | 2017 |
| Metric | BHR | SPRO |
|---|---|---|
| Price | $2.28 | $2.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 354.9K | 280.6K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 8.58% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | ★ N/A | $16.20 |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $1.80 | $0.51 |
| 52 Week High | $3.19 | $3.09 |
| Indicator | BHR | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 37.03 | 53.51 |
| Support Level | $2.06 | $2.15 |
| Resistance Level | $2.70 | $2.44 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 33.33 | 44.90 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.